|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SAP30 |
Gene summary for SAP30 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SAP30 | Gene ID | 8819 |
| Gene name | Sin3A associated protein 30 | |
| Gene Alias | SAP30 | |
| Cytomap | 4q34.1 | |
| Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | O75446 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 8819 | SAP30 | HCC1_Meng | Human | Liver | HCC | 1.45e-07 | 2.01e-02 | 0.0246 |
| 8819 | SAP30 | HCC2_Meng | Human | Liver | HCC | 7.51e-03 | 4.53e-02 | 0.0107 |
| 8819 | SAP30 | HCC2 | Human | Liver | HCC | 2.81e-02 | 1.21e+00 | 0.5341 |
| 8819 | SAP30 | S014 | Human | Liver | HCC | 1.18e-04 | 1.06e-01 | 0.2254 |
| 8819 | SAP30 | S016 | Human | Liver | HCC | 3.89e-02 | 1.04e-01 | 0.2243 |
| 8819 | SAP30 | S027 | Human | Liver | HCC | 5.32e-10 | 6.13e-01 | 0.2446 |
| 8819 | SAP30 | S028 | Human | Liver | HCC | 4.78e-17 | 6.99e-01 | 0.2503 |
| 8819 | SAP30 | S029 | Human | Liver | HCC | 6.22e-24 | 7.83e-01 | 0.2581 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:001657015 | Esophagus | ESCC | histone modification | 323/8552 | 463/18723 | 2.61e-26 | 7.88e-24 | 323 |
| GO:000961518 | Esophagus | ESCC | response to virus | 238/8552 | 367/18723 | 6.65e-14 | 3.32e-12 | 238 |
| GO:0044403111 | Esophagus | ESCC | biological process involved in symbiotic interaction | 186/8552 | 290/18723 | 1.43e-10 | 4.16e-09 | 186 |
| GO:003105614 | Esophagus | ESCC | regulation of histone modification | 106/8552 | 152/18723 | 1.52e-09 | 3.55e-08 | 106 |
| GO:00356015 | Esophagus | ESCC | protein deacylation | 79/8552 | 112/18723 | 8.30e-08 | 1.42e-06 | 79 |
| GO:00987325 | Esophagus | ESCC | macromolecule deacylation | 80/8552 | 116/18723 | 3.19e-07 | 4.50e-06 | 80 |
| GO:00165754 | Esophagus | ESCC | histone deacetylation | 60/8552 | 82/18723 | 3.85e-07 | 5.32e-06 | 60 |
| GO:00310583 | Esophagus | ESCC | positive regulation of histone modification | 65/8552 | 92/18723 | 1.04e-06 | 1.31e-05 | 65 |
| GO:00064765 | Esophagus | ESCC | protein deacetylation | 70/8552 | 101/18723 | 1.29e-06 | 1.58e-05 | 70 |
| GO:005185115 | Esophagus | ESCC | modulation by host of symbiont process | 43/8552 | 60/18723 | 4.00e-05 | 3.22e-04 | 43 |
| GO:005181714 | Esophagus | ESCC | modulation of process of other organism involved in symbiotic interaction | 54/8552 | 81/18723 | 1.09e-04 | 7.64e-04 | 54 |
| GO:00903122 | Esophagus | ESCC | positive regulation of protein deacetylation | 20/8552 | 25/18723 | 4.81e-04 | 2.69e-03 | 20 |
| GO:003582114 | Esophagus | ESCC | modulation of process of other organism | 64/8552 | 106/18723 | 1.61e-03 | 7.50e-03 | 64 |
| GO:005170214 | Esophagus | ESCC | biological process involved in interaction with symbiont | 57/8552 | 94/18723 | 2.46e-03 | 1.07e-02 | 57 |
| GO:00310652 | Esophagus | ESCC | positive regulation of histone deacetylation | 15/8552 | 19/18723 | 3.29e-03 | 1.35e-02 | 15 |
| GO:00310631 | Esophagus | ESCC | regulation of histone deacetylation | 21/8552 | 31/18723 | 1.10e-02 | 3.70e-02 | 21 |
| GO:00903114 | Esophagus | ESCC | regulation of protein deacetylation | 30/8552 | 48/18723 | 1.40e-02 | 4.57e-02 | 30 |
| GO:004440312 | Liver | Cirrhotic | biological process involved in symbiotic interaction | 131/4634 | 290/18723 | 2.00e-14 | 1.84e-12 | 131 |
| GO:00518171 | Liver | Cirrhotic | modulation of process of other organism involved in symbiotic interaction | 44/4634 | 81/18723 | 1.11e-08 | 4.26e-07 | 44 |
| GO:005170211 | Liver | Cirrhotic | biological process involved in interaction with symbiont | 48/4634 | 94/18723 | 3.41e-08 | 1.14e-06 | 48 |
| Page: 1 2 3 4 5 6 7 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0516921 | Liver | HCC | Epstein-Barr virus infection | 128/4020 | 202/8465 | 3.17e-06 | 2.79e-05 | 1.55e-05 | 128 |
| hsa0516931 | Liver | HCC | Epstein-Barr virus infection | 128/4020 | 202/8465 | 3.17e-06 | 2.79e-05 | 1.55e-05 | 128 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| SAP30 | TAC | Colorectum | AD | HMGB2,MXD3,KIF20A, etc. | 2.01e-01 |  |
| SAP30 | TAC | Colorectum | ADJ | SAP30(+) | 2.90e-01 |  |
| SAP30 | TAC | Colorectum | MSI-H | HMGB2,MXD3,KIF20A, etc. | 4.83e-01 |  |
| SAP30 | TAC | Colorectum | MSS | HMGB2,MXD3,KIF20A, etc. | 4.56e-01 |  |
| SAP30 | GOB | Colorectum | MSS | HMGB2,MXD3,KIF20A, etc. | 7.07e-03 | |
| SAP30 | EE | Colorectum | MSS | HMGB2,MXD3,KIF20A, etc. | 3.03e-03 | |
| SAP30 | CT | Colorectum | MSS | HMGB2,MXD3,KIF20A, etc. | 0.00e+00 | |
| SAP30 | TAC | Colorectum | SER | HMGB2,MXD3,KIF20A, etc. | 2.14e-01 |  |
| SAP30 | CILIA | Endometrium | ADJ | HMGB3,BNIP3,GSN, etc. | 2.85e-01 |  |
| SAP30 | CILIA | Endometrium | AEH | HMGB3,BNIP3,GSN, etc. | 3.02e-01 |  |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 2 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SAP30 | SNV | Missense_Mutation | c.446N>T | p.Asp149Val | p.D149V | O75446 | protein_coding | deleterious(0) | probably_damaging(0.99) | TCGA-D8-A1XQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| SAP30 | SNV | Missense_Mutation | c.368N>A | p.Arg123Gln | p.R123Q | O75446 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| SAP30 | SNV | Missense_Mutation | novel | c.538G>A | p.Glu180Lys | p.E180K | O75446 | protein_coding | tolerated(0.09) | probably_damaging(0.989) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| SAP30 | SNV | Missense_Mutation | novel | c.374N>A | p.Arg125Lys | p.R125K | O75446 | protein_coding | tolerated(1) | benign(0.137) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| SAP30 | SNV | Missense_Mutation | novel | c.624N>T | p.Lys208Asn | p.K208N | O75446 | protein_coding | deleterious(0.01) | probably_damaging(0.991) | TCGA-AJ-A3EL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| SAP30 | SNV | Missense_Mutation | c.521N>C | p.Asn174Thr | p.N174T | O75446 | protein_coding | tolerated(0.24) | probably_damaging(0.989) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| SAP30 | SNV | Missense_Mutation | c.368N>A | p.Arg123Gln | p.R123Q | O75446 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-AP-A1E1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| SAP30 | SNV | Missense_Mutation | c.585N>A | p.Asp195Glu | p.D195E | O75446 | protein_coding | tolerated(1) | benign(0.207) | TCGA-AX-A2HJ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| SAP30 | SNV | Missense_Mutation | c.368G>A | p.Arg123Gln | p.R123Q | O75446 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-BS-A0UF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| SAP30 | SNV | Missense_Mutation | c.368N>A | p.Arg123Gln | p.R123Q | O75446 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-BS-A0UV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |